Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)

Next Previous
Trial Profile

A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerdulatinib (Primary) ; Rituximab
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

  • 01 Jun 2025 Results assessing cerdulatinibin relapsed/refractory peripheral T-cell lymphoma, published in the Leukemia and Lymphoma
  • 14 Dec 2021 Final Results from the PTCL cohort (n=65) assessing efficacy and safety of cerdulatinib monotherapy, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results (n=42) assessing the efficacy and safety data are presented for pts in the two FL cohorts, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top